



5835 Peachtree Corners East, Suite D
Norcross, GA 30092

Contact

Media: Bill Wells – 770-242-8723

Top Doctors to Present Results of FDA Clinical Trial of Guided Therapeutics' Cervical Cancer Detection Technology at Scientific Meeting

Five Presentations scheduled for American Society for Colposcopy and Cervical Pathology Meeting

NORCROSS, GA (February 23, 2010) – Results of the U.S. Food and Drug Administration (FDA) pivotal clinical trial for the [Guided Therapeutics, Inc.](#) (GT) (Pink Sheets: GTHP) LightTouch™ Non-invasive Cervical Cancer Detection System are scheduled to be presented by five leading doctors at the American Society for Colposcopy and Cervical Pathology biennial meeting, March 24 – 27, 2010, in Las Vegas.

“Having five peer-reviewed presentations, submitted by recognized experts from nine leading medical institutions, is a testament to the potential for our technology to have a positive affect on women’s health,” said Mark L. Faupel, Ph.D., President and CEO of GT. “We are pleased that the presentation authors, all of whom are leaders in women’s health care, support the LightTouch technology and have agreed to speak to its potential for the early detection of cervical cancer.”

In addition to the five peer-reviewed presentations that are scheduled to be published in the meeting proceedings, GT will have a working LightTouch system, including the single-use calibration and patient interface, on display.

The presentation abstract titles and authors are:

MULTIMODAL SPECTROSCOPY AS A TRIAGE TEST FOR WOMEN AT RISK FOR CERVICAL NEOPLASIA: RESULTS OF A 1,607 SUBJECT PIVOTAL TRIAL

Twiggs LB, Chakhtoura NA, University of Miami, Miami, Florida, Werner CL, Griffith WF, University of Texas Southwestern Medical Center, Dallas, Texas, Flowers LC, University of Emory School of Medicine, Atlanta, Georgia, Lashgari M, University of Connecticut, Hartford, Connecticut, Ferris DG, Medical College of Georgia, Augusta, Georgia, Winter ML, Orange Coast Women’s Medical Group, Laguna Hills, California, Sternfeld DR, Saddleback Women’s Medical Group, Laguna Hills, California, Burnett AF, University of Arkansas, Little Rock, Arkansas, Wilkinson EJ, University of Florida, Gainesville, Florida, Raab SS, University of Colorado, Denver, Colorado

MULTIMODAL SPECTROSCOPY AS A TRIAGE TEST FOR WOMEN AT RISK FOR CERVICAL NEOPLASIA: RESULTS FOR ADOLESCENT SUBJECTS

Flowers, LC, Tadros, TS; Emory University School of Medicine, Atlanta, Georgia

MULTIMODAL SPECTROSCOPY AS A TRIAGE TEST FOR WOMEN AT RISK FOR CERVICAL NEOPLASIA: HISTOPATHOLOGY REVIEW PROCEDURES AND RESULTS

Wilkinson EJ, Raab SS; University of Florida, Department of Pathology, Gainesville, Florida, University of Colorado at Denver and Health Sciences Center, Department of Pathology, Denver, Colorado

####MORE####

MULTIMODAL SPECTROSCOPY AS A TRIAGE TEST FOR WOMEN AT RISK FOR CERVICAL NEOPLASIA: RESULTS OF FOLLOW UP DATA

Chakhtoura NA, Twiggs LB, University of Miami, Miami, Florida, Wilkinson EJ, University of Florida, Gainesville, Florida, Raab SS, University of Colorado, Denver, Colorado

MULTIMODAL SPECTROSCOPY AS A TRIAGE TEST FOR WOMEN AT RISK FOR CERVICAL NEOPLASIA: EXPERIENCE WITH A LOW COST COMMERCIAL PROTOTYPE

Winter ML, Sternfeld DR, Orange Coast Women’s Medical Group, Laguna Hills, CA, Saddleback Women’s Medical Group, Laguna Hills, CA

The 2010 biennial meeting of the American Society for Colposcopy and Cervical Pathology is planned for March 24 – 27, 2010, at the Green Valley Ranch Resort in Las Vegas, Nevada. For more information, visit www.asccp.org.

About Guided Therapeutics

Guided Therapeutics, Inc. ([Pink Sheets: GTHP](#)) is developing a rapid and painless test for the early detection of disease that leads to cervical cancer. The technology is designed to provide an objective result at the point of care thereby improving the management of cervical disease. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are known immediately. The company also owns technology for measuring substances in interstitial fluid, a secondary circulatory system in the body that surrounds the cells. For more information, visit GT’s web site www.guidedinc.com.

The Guided Therapeutics LightTouch™ Non-invasive Cervical Cancer Detection System is an investigational device and is limited by federal law to investigational use.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-KA for the fiscal year ended December 31, 2008 and subsequent quarterly reports.

###END###